Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714

Toxicological Sciences

Volumn 108, Issue 2, 2009, Pages 492-500

  Feng, Bo ^a   Xu, Jinghai J ^b   Bi, Yi An ^a   Mireles, Rouchelle ^a   Davidson, Ralph ^a   Duignan, David B ^a   Campbell, Scott ^c   Kostrubsky, Vsevolod E ^d   Dunn, Margaret C ^a   Smith, Arthur R ^e   Wang, Huifen F ^a  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e Health Advances   (United States)

Author keywords

CP 724,714; Hepatic transporters; Hepatocytes; Hepatotoxicity; Mechanism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHOLYLLYSYL FLUORESCEIN; CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUORESCEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL TRANSPORT; CHOLESTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CLEARANCE; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG STRUCTURE; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRAHEPATIC BILE DUCT; LIVER CELL; LIVER CELL DAMAGE; LIVER TOXICITY; TOXICOKINETICS;

ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILE ACIDS AND SALTS; CALCIUM; CARRIER PROTEINS; CELLS, CULTURED; ENZYME INHIBITORS; FLUORESCEINS; HEPATITIS, TOXIC; HEPATOCYTES; HUMANS; LIVER; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORT POLYPEPTIDE C; P-GLYCOPROTEIN; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 64349086181     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp033     Document Type: Article

References (31)

1. Bi, Y. A., Kazolias, D., and Duignan, D. B. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos. 34, 1658-1665.
2. Büchler, M., Konig, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T., and Keppler, D. (1996). cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271, 15091-15098.
3. Byrne, J. A., Strautnieks, S. S., Mieli-Vergani, G., Higgins, C. F., Linton, K. J., and Thompson, R. J. (2002). The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 123, 1733-1735.
4. Campbell, S. D., de Morais, S. M., and Xu, J. J. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150, 179-187.
5. Cui, Y., Konig, J., Leier, I., Buchholz, U., and Keppler, D. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276, 9626-9630.
6. Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., and de Morais, S. M. (2008). In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36, 268-275.
7. Guo, F., Letrent, S. P., Munster, P. N., Britten, C. D., Gelmon, K., Tolcher, A. W., and Sharma, A. (2008). Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: Correlations with clinical characteristics and safety. Cancer Chemother. Pharmacol. 62, 97-109.
8. Hallifax, D., and Houston, J. B. (2006). Uptake and intracellular binding of lipophilicamine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab. Dispos. 34, 1829-1836.
9. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., and Sugiyama, Y. (2005). Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68, 800-807.
10. Hofmann, A. F. (2007). Biliary secretion and excretion in health and disease: Current concepts. Ann. Hepatol. 6, 15-27.
11. Jani, J. P., Finn, R. S., Campbell, M., Coleman, K. G., Connell, R. D., Currier, N., Emerson, E. O., Floyd, E., Harriman, S., Kath, J. C., et al. (2007). Discovery and pharmacologic characterization of CP-724,714, a selective erbB2 tyrosine kinase inhibitor. Cancer Res. 67, 9887-9893.
12. Jansen, P. L., Strautnieks, S. S., Jacquemin, E., Hadchouel, M., Sokal, E. M., Hooiveld, G. J., Koning, J. H., De Jager-Krikken, A., Kuipers, F., Stellaard, F., et al. (1999). Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117, 1370-1379.
13. Kalgutkar, A. S., Feng, B., Nguyen, H. T., Frederick, K. S., Campbell, S. D., Hatch, H. L., Bi, Y. A., Kazolias, D. C., Davidson, R. E., Mireles, R. J., et al. (2007). Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}- methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metab. Dispos. 35, 2111-2118.
14. Keitel, V., Kartenbeck, J., Nies, A. T., Spring, H., Brom, M., and Keppler, D. (2000). Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32, 1317-1328.
15. Kim, R. B. (2006). Transporters and drug discovery: Why, when and how. Mol. Pharm. 3, 26-32.
16. Klaassen, C. D. (1973). Comparison of the toxicity of chemicals in newborn rats to bile duct ligated and sham operated rats and mice. Toxicol. Appl. Pharmacol. 24, 37-44.
17. Kostrubsky, V. E., Strom, S. C., Hanson, J., Urda, E., Rose, K., Burliegh, J., Zocharski, P., Sinclai, J. F., and Sahi, J. (2003). Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76, 220-228.
18. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
19. Kostrubsky, S. E., Strom, S. C., Ellis, E., Nelson, S. D., and Mutlib, A. E. (2007). Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. Chem. Res. Toxicol. 20, 1503-1512.
20. Liu, X., Chism, J. P., LeCluyse, E. L., Brouwer, K. R., and Brouwer, K. L. (1999a). Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos. 27, 637-644.
21. Liu, X., LeCluyse, E. L., Brouwer, K. R., Gan, L.-S., Lemasters, J. J., Stieger, B., Meier, P. J., and Brouwer, K. L. (1999b). Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 40, G12-G21.
22. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S., and Abe, T. (2004). The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19, 171-179.
23. Morita, N., Kusuhara, H., Nozaki, Y., Endou, H., and Sugiyama, Y. (2005). Functional involvement of rat organic anion transporter 2 (SLC22A7) in the hepatic uptake of the nonsteroidal anti-inflammatory drug ketoprofen. Drug Metab. Pharmacokinet. 33, 1151-1157.
24. Munster, P. N., Britten, C. D., Mita, M., Gelmon, K., Minton, S. E., Moulder, S., Slamon, D. J., Guo, F., Letrent, S. P., Denis, L., et al. (2007). First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin. Cancer Res. 13, 1238-1245.
25. Pauli-Magnus, C., and Meier, P. J. (2006). Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44, 778-787.
26. Shitara, Y., Horie, T., and Sugiyama, Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425-446.
27. Thompson, R., and Strautnieks, S. (2001). BSEP: Function and role in progressive familial intrahepatic cholestasis. Semin. Liver Dis. 21, 545-550.
28. Vallejo, M., Briz, O., Serrano, M. A., Monte, M. J., and Marin, J. J. (2006). Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J. Hepatol. 44, 1150-1157.
29. Xiao, Y., Davidson, R., Smith, A., Pereira, D., Zhao, S., Soglia, J., Gebhard, D., de Morais, S., and Duignan, D. B. (2006). A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol. Pharmacol. 3, 45-54.
30. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.
31. Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y., and Iga, T. (2001). Prediction of midazolam-cyp3a inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab. Dispos. 29, 443-452.